Table 3 Group assignment in murine model of RSV challenge

From: A lyophilised formulation of chimpanzee adenovirus vector for long-term stability outside the deep-freeze cold chain

Group#

Group name

Description

Storage at 5 °C, Months

Total viral particles

No.mice

Sample collection, days

Serum

Whole blood

Spleen

Lungs

1

Frozen (Ph1)*

Frozen ChAd155

-

1 × 108

15

35, 40

14, 28, 34

35, 40

40

2

Lyo-T0

Lyophilised ChAd155

0

1 × 108

15

35, 40

14, 28, 34

35, 40

40

3

Lyo-T0

Lyophilised ChAd155

0

3 × 106

15

35, 40

14, 28, 34

35, 40

40

4

LyoT24

Lyophilised ChAd155

24

1 × 108

15

35, 40

14, 28, 34

35, 40

40

5

LyoT24

Lyophilised ChAd155

24

3 × 106

15

35, 40

14, 28, 34

35, 40

40

6

FI-RSV

Formalin-inactivated RSV

-

-

15

35, 40

14, 28, 34

35, 40

40

7

Live RSVA2

Challenge RSV

-

1 × 106 **

15

35, 40

14, 28, 34

35, 40

40

8

PBS

PBS

-

-

15

35, 40

14, 28, 34

35, 40

40

9

Frozen (Ph1)*

Frozen ChAd155

-

1 × 107

5

35

14, 28, 34

35

-

10

Frozen (Ph1)*

Frozen ChAd155

-

3 × 106

5

35

14, 28, 34

35

-

11

Lyo-T0

Lyophilised ChAd155

0

1 × 107

5

35

14, 28, 34

35

-

12

LyoT24

Lyophilised ChAd155

24

1 × 107

5

35

14, 28, 34

35

-

  1. *Ph1 indicates that the vaccine was for clinical use at Phase 1. **The challenge RSV was titred by plaque-forming units (pfu).
Back to article page